Tango Therapeutics Inc
(NAS:TNGX)
$
9.982
0.31 (3.2%)
Market Cap: 1.07 Bil
Enterprise Value: 752.88 Mil
PE Ratio: 0
PB Ratio: 4.18
GF Score: 52/100 Tango Therapeutics Inc at H.C. Wainwright Precision Oncology Conference (Virtual) Transcript
Nov 14, 2022 / 04:00PM GMT
Release Date Price:
$8.15
(+5.03%)
Robert Burns
H.C. Wainwright & Co. - Analyst
Welcome to the next fireside chat with Tango Therapeutics. I'm Robert Burns, Managing Director and Senior Biotech Analyst at H.C. Wainwright. And I'm joined today by Barbara Weber, the CEO of Tango. Barbara, thank you for joining us today.
Barbara Weber
Tango Therapeutics, Inc. - President and CEO
Thanks for having me.
Questions & Answers
Robert Burns
H.C. Wainwright & Co. - Analyst
So why don't we just dive right in? For those who may be unfamiliar with Tango, could you provide a brief overview of the company's screening platform as well as its pipeline?
Barbara Weber
Tango Therapeutics, Inc. - President and CEO
Yes, thanks. Starting with really the basic idea is that there are activated oncogenes in cancer that can be targeted. But equally important, there are tumor suppressor genes that are lost. And tumor suppressor genes that are lost cannot be directly targeted because they're gone or functionally
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot